• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Clinical trial at CU Anschutz will test injectable vs. oral medications to treat HIV

Bioengineer by Bioengineer
May 9, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Many forget to take daily pills, experimental injectable drugs last longer

Researchers at the University of Colorado Anschutz Medical Campus, working with the National Institutes of Health, will conduct a clinical trial beginning this month to determine if monthly injections of anti-viral drugs are more effective at suppressing the HIV virus than daily pills in a population for whom daily adherence has been a challenge.

Over the years, HIV has moved from a nearly uniformly fatal disease to a chronic one that can be managed with medication. But many patients still face obstacles to taking the daily medications which keep the virus dormant, leading to a potentially dangerous flare up.

“When they are taking their pills, the virus becomes undetectable,” said Jose Castillo-Mancilla, MD, associate professor of medicine at the University of Colorado School of Medicine. “But you need to take your pills. And sometimes taking pills is hard due to life circumstances.”

The trial is called Long-Acting Therapy to Improve Treatment Success in Daily Life or LATITUDE. It will examine whether two experimental injectable drug formulations of antiretroviral therapy (ART) are more effective than daily pills.

Castillo-Mancilla, an infectious disease expert, is co-chair of LATITUDE. He said the injectables could keep steady drug concentrations in the blood, unlike oral medications if doses are missed.

The injectable drugs, rilpivirine (RPV) and cabotegravir (CAB), will be given every four weeks. Investigators will measure the virus in the blood throughout the study and compare it with those taking pills.

Approximately 350 volunteers with documented treatment lapses within the last 18 months will be enrolled in the trial for 52 weeks.

Currently, there are about 1.1 million people with HIV in the U.S. That number is approximately 40 million worldwide.

“It is not a curable epidemic but it is a controllable one,” Castillo-Mancilla said. “We believe we can get to zero transmission. The generous volunteers who enroll in this study will help ensure that more people living with HIV may have more effective treatment regimens that work for them.”

The trial is being conducted by the AIDS Clinical Trials Group with additional support from the NIH’s National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; the National Institute on Drug Abuse; ViiV Healthcare and the Janssen Pharmaceutical Companies of Johnson & Johnson.

###

About the University of Colorado Anschutz Medical Campus

The largest academic health center in the Rocky Mountain region, the University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education, and healthcare. The campus encompasses the University of Colorado health professional schools, numerous centers and institutes, and two nationally ranked hospitals that treat more than 2 million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, together we deliver life-changing treatments, patient care, and professional training, and conduct world-renowned research powered by more than $500 million in research awards.

Media Contact
Julia Milzer
[email protected]

Tags: AIDS/HIVAlternative MedicineClinical TrialsMedicine/HealthMortality/LongevityPublic HealthQuality of LifeSexual OrientationToxicology
Share13Tweet7Share2ShareShareShare1

Related Posts

UBCO Study Reveals Sex Education Falls Short for 2SLGBTQIA+ Students

October 7, 2025

MiR-140-3p Impairs KIF5A, Drives SMA Transport Degeneration

October 7, 2025

Evaluating the CCCQ for Chinese Cancer Caregivers

October 7, 2025

Soft Bioelectronics with DNA Circuit Monitor Wounds

October 7, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    884 shares
    Share 353 Tweet 221
  • New Study Reveals the Science Behind Exercise and Weight Loss

    98 shares
    Share 39 Tweet 25
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    94 shares
    Share 38 Tweet 24
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    76 shares
    Share 30 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

FIU Cybersecurity Experts Unveil Midflight Defense Mechanism to Prevent Drone Hijacking

UBCO Study Reveals Sex Education Falls Short for 2SLGBTQIA+ Students

Covalent Organic Frameworks: Building Infinite Metal–Organic Structures

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.